OnKure Therapeutics financials
$2.60−5.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$16.9M | -$15.6M | -$14.1M | -$15.5M | -$16.3M | -$17.0M | -$18.7M |
| Net income | -$15.3M | -$15.2M | -$13.5M | -$14.7M | -$15.4M | -$15.9M | -$17.4M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-0.31 | $-1.11 | $-0.99 | $-1.09 | $-1.14 | $-1.19 | $-1.36 |
| EBITDA | -$16.8M | -$15.5M | -$14.0M | -$15.4M | -$16.2M | -$16.9M | -$18.6M |
| Operating cash flow | -$10.4M | -$12.9M | -$11.5M | -$13.0M | -$13.3M | -$14.0M | -$23.4M |
| Free cash flow | -$10.4M | -$12.9M | -$11.5M | -$13.0M | -$13.3M | -$14.0M | -$23.4M |
| Diluted shares | 49.9M | 13.7M | 13.6M | 13.5M | 13.5M | 13.4M | 12.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $166.5M | $192.1M | $59.0M | $70.3M | $83.4M | $96.7M |
| Short-term investments | $9.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $179.4M | $198.7M | $62.1M | $72.8M | $86.1M | $99.9M |
| Total liabilities | $7.2M | $14.3M | $5.9M | $6.4M | $7.9M | $9.2M |
| Shareholders' equity | $172.1M | $184.4M | $56.2M | $66.4M | $78.2M | $90.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology